Coagulation dysfunction and thrombosis are major complications in patients with
coronavirus disease 2019 (COVID‐19). Patients on oral anticoagulants (OAC) prior to …

Data on the prognosis of patients treated with oral anticoagulation (OAC) prior to hospital
admission for COVID-19 remains controversial and insufficient. Therefore, we endeavored to …

Background. Most evidence regarding anticoagulation and COVID‐19 refers to the
hospitalization setting, but the role of oral anticoagulation (OAC) before hospital admission …

Introduction There are conflicting data on prior oral-anticoagulant (OAC) use and outcomes
of hospitalized COVID-19 patients. Due to uncertainties regarding associated risks with the …

Aims Coagulopathy and venous thromboembolism are common findings in coronavirus
disease 2019 (COVID-19) and are associated with poor outcome. Timely initiation of …

The hypercoagulable state observed in COVID‐19 could be responsible for morbidity and
mortality. In this retrospective study we investigated whether therapeutic anticoagulation …

Background Venous thromboembolism has been reported in patients with coronavirus
disease 2019 (COVID-19). It remains unclear if premorbid use of prophylactic oral …

Background The coronavirus disease 2019 (COVID‐19) shows high morbidity and mortality,
particularly in patients with concomitant cardiovascular diseases. Some of these patients are …

Background COVID-19 is associated with hypercoagulability and an increased incidence of
thrombosis. We evaluated the clinical outcomes of adults hospitalized with COVID-19 who …

Abstract Coronavirus disease 2019 (COVID-19) is associated with a high incidence of
venous and arterial thromboembolic events. The role of anticoagulation (AC) prior to …